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Abstract: Therapeutic methods directed at alleviating the basic pathological processes of 
normal-tension glaucoma (NTG) are yet to be established. Although there seems to be little 
doubt that intraocular pressure (IOP) represents a risk factor in most patients, reduction of 
IOP does not prevent progression in every patient with NTG, indicating that factors other 
than elevated IOP are involved in glaucoma progression. New avenues of treatment under 
investigation include agents that could improve blood ﬂ  ow to the eye and neuroprotective 
drugs. The major components of the renin-angiotensin system have been identiﬁ  ed in ocular 
tissue. Angiotensin-converting enzyme (ACE) inhibitors are widely used to treat systemic 
hypertension. ACE inhibitors are inhibitors of kininase II and thus prevent breakdown of 
bradykinin. Bradykinin displays protective actions against glutamate neurotoxicity through 
bradykinin-B2 receptors in cultured retinal neurons. ACE inhibitors blocked the liberation of 
angiotensin II from angiotensin I. Lower angiotensin II levels may have beneﬁ  cial effects on 
outcomes by lowering vascular superoxide anion production. The effects of ACE inhibitor as 
a potential antiglaucoma therapy deserve intense scrutiny.
Keywords: glaucoma, angiotensin-converting enzyme inhibitor, bradykinin, neuroprotection, 
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Introduction
Normal-tension glaucoma (NTG) refers to a glaucomatous optic nerve head change 
and corresponding glaucomatous visual ﬁ  eld defects without elevated intraocular 
pressure (IOP). A long-term collaborative study conducted in North America and 
Europe revealed that a 30% reduction in IOP exerted positive effects on the progression 
of visual ﬁ  eld loss in NTG (Collaborative Normal-Tension Glaucoma Study Group 
1998a). Treatment goals for open-angle glaucoma have focused almost exclusively 
on lowering IOP using drugs, laser therapy or surgery. However, many investigators 
believe that IOP is not the only factor causally related to glaucomatous optic nerve 
changes and that some factors unrelated to IOP play signiﬁ  cant roles in at least 
some NTG cases. Patients with glaucoma in whom IOP is lowered to within normal 
range often continue to suffer further progressive damage (Mao et al 1991; Nouri-
Mahdavi et al 1995). A recent 10-year follow-up study showed a direct correlation 
between IOP levels and stabilization of the optic disc and visual ﬁ  eld (Araujo et al 
1995). Still, 10% of patients in that study with a mean ﬁ  nal IOP of 13 mmHg continued 
to show disease progression.
The association of glaucoma with various systemic vascular diseases includ-
ing low systemic blood pressure, transient nocturnal decreases in blood pressure, 
hypertension, migraine, vasospasm and diabetes has been reported (Flammer et al 
1999; Hayreh 1999; Bonomi et al 2000; Drance et al 2001). Many patients with 
chronic open-angle glaucoma present with coexisting vascular disorders, the most 
common of which is systemic hypertension, which occurs in 48% of the total chronic Clinical Ophthalmology 2007:1(3) 218
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open-angle glaucoma population (Gottfredsdottir et al 
1997). Pharmacological treatment of non-IOP-dependent 
mechanisms in glaucoma has largely been limited to the use 
of calcium-channel blockers, which are widely used in the 
treatment of systemic hypertension, coronary artery diseases, 
stroke and arrhythmias. The jury is still out on the contrast-
ing results for systemic calcium-channel blockers used on 
human glaucoma patients. Calcium-channel blockers may 
increase blood ﬂ  ow to the optic nerve head (Tomita et al 
1999) and might be particularly useful in patients with NTG 
(Netland et al 1993; Kancllopoulos et al 1996). However, 
one study showed no signiﬁ  cant difference in progression of 
glaucoma in patients using or not using systemic calcium-
channel blockers (Liu et al 1996). Systemic calcium channel 
blockers can also have adverse cardiac effects, particu-
larly if the patient is being treated with topical β-blockers 
(Kancllopoulos et al 1996).
Neuroprotection refers to the post-injury protection of 
neurons that were initially undamaged or only marginally 
damaged by a particular insult, but are at risk from toxic 
stimuli released by damaged cells, causing secondary degen-
eration (Yoles and Schwartz 1998). Secondary degeneration 
refers to the spread of degeneration to apparently healthy 
neurons that escape the primary insult, but are adjacent to 
injured neurons and thus exposed to the degenerative milieu 
that results (Yoles and Schwartz 1998).
Renin-angiotensin system
The renin-angiotensin system (RAS) plays an important 
role in vasoconstriction, regulation of electrolyte balance 
and vascular remodeling. Local renin-angiotensin regulation 
is present in the eye (Danser et al 1994; Wagner et al 1996). 
Since the initial application of angiotensin-converting enzyme 
(ACE) inhibitors as therapeutic agents for the treatment of 
hypertension, several additional clinical indications have 
been identiﬁ  ed and approved (Brown and Vaughan 1998). 
ACE inhibitor activity reportedly improves endothelial 
function and stimulates vascular remodeling, in addition to 
attenuating progression of arteriosclerosis and the occurrence 
of cardiovascular events in humans (Mancini et al 1996; 
Yusuf et al 2000). The identiﬁ  cation of ACE as a signaling 
molecule, which can be activated by the binding of ACE 
inhibitor, may account for some of the beneﬁ  cial effects of 
this class of compounds on the cardiovascular system.
The RAS is an enzymatic cascade that generates a range 
of angiotensin peptides with varying biological actions. 
Deﬁ  nitive evidence that an RAS exists within the eye has 
been provided by molecular biological techniques such as 
real-time PCR and RNAse protection assays, which have 
revealed that components of the RAS are synthesized in 
ocular tissue. Renin is expressed in the pigmented epithelium 
and retinal Müller cells (Berka et al 1995; Wagner et al 
1996). Angiotensinogen is the sole precursor of angiotensin 
peptides and is cleaved to generate angiotensin I by renin 
and aspartyl proteases (Figure 1). Angiotensin II can be 
liberated from angiotensin I by ACE or serine proteases. 
Angiotensin II is the main effector peptide of the RAS 
and acts on two main receptor subtypes: angiotensin type I 
(AT1); and angiotensin type II (AT2). Gene expression for
AT1 and AT2 receptors has been identiﬁ  ed in several ocu-
lar tissues, including the retina (Brandt et al 1994; Murata 
et al 1997; Wheeler-Schilling et al 1999; Sarlos et al 2003). 
Angiotensinogen
Prorenin rennin kallikrein
Angiotensin I Bradykinin
ACE
Angiotensin II Inactive
Fragments
Kininogen 
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AT1 receptors have been localized to the ganglion cell layer 
and inner nuclear layer in rat retina (Wheeler-Schilling et al 
1999). AT1 receptor elicits most of the known physiological 
actions of angiotensin II, including vasoconstriction, elec-
trolyte homeostasis, modulation of drinking behavior and 
stimulation of pituitary hormone release (Culman et al 1995; 
Ito et al 1995; Aguilera and Kiss 1996). In tissue pathology 
such as cardiovascular disease, nephropathies, liver cirrhosis 
and cancer, AT1 receptor is implicated in a wide variety of 
cell events including cell growth, differentiation and migra-
tion, ﬁ  brosis and inﬂ  ammation and angiogenesis (Yoshiji 
et al 2001; Yoshiji et al 2002; Brewster et al 2003; Gilbert 
et al 2003; Muller et al 2003). Actions of the AT2 receptor 
are less well deﬁ  ned, but possibly oppose actions of the AT1 
receptor, including vasodilation and apoptosis (Chung et al 
1998). However, evidence in a number of tissues suggests 
that the AT2 receptor displays similar actions to the AT1 
receptor, promoting cell growth and angiogenesis (Levy et al 
1996; Cao et al 2000; Sarlos et al 2003).
The kallikrein-kinin system
In general, the kallikrein-kinin system is thought to coun-
terbalance the activities of the RAS. Kinin peptides are 
generated from kininogens by kallikrein, a serine protease 
(Figure 1). The actions of kinin peptides include promoting 
inﬂ  ammation, leakage of plasma proteins, pain and more 
recently, angiogenesis.
Components of the kallikrein-kinin system have been 
identiﬁ  ed in the eye. Kallikrein and kininase II activity are 
found in the retina, choroid and ciliary body of swine eyes, 
with the highest activity of kininase I in aqueous humor 
(Igic 1985). Bradykinin is a vasodilating nonapeptide that 
is degraded by ACE (Hornig and Drexler 1997). Plasma 
bradykinin levels are increased in patients treated with ACE 
inhibitor (Cugno et al 2005). Bradykinin displays a wide 
range of actions, mediated through at least two subtypes of 
receptor: B1 and B2 (Regoli and Barabe 1980). B1 receptor 
has been implicated in angiogenesis, as bradykinin stimu-
lates endothelial cell proliferation in vitro via activation of 
the B1 receptor cAMP pathway (Morbiddelli et al 1998). 
Most biological actions are mediated by B2 receptors. 
Bradykinin-B2 receptors are reportedly abundantly distrib-
uted in vascular tissues and smooth muscles cell, and also in 
human brain (Raidoo et al 1996) and retinal (Ma et al 1996) 
neurons. In human retina, tissue kallikrein, low molecular 
weight kininogen and B1 and B2 receptors are expressed in 
neuronal cells of the outer nuclear layer, inner nuclear layer 
and ganglion cell layer, and on the retinal vasculature   
(Ma et al 1996). In addition, mRNA for the B2 receptor has 
been identiﬁ  ed in the retinal ganglion cell layer and in a 
population of cells adjacent to the sclerocorneal junction in 
rats (Takeda et al 1999). In B2 receptor-deﬁ  cient mice with 
hindlimb ischemia, ACE inhibition increased vessel density 
and capillary number in the ischemic leg (Silvestre et al 
2001). This was not observed in the ischemic hindlimb of 
mice lacking B2 receptor (Silvestre et al 2001).
Blood ﬂ  ow
AT1 receptor antagonist ameliorates impaired optic nerve 
head blood ﬂ  ow in rabbits (Inoue et al 2003). The decreased 
ﬂ  ow velocity in hypertensive patients improved with an oral 
ACE inhibitor (Steigerwalt et al 1998). ACE inhibitor may 
act in several ways to increase the blood ﬂ  ow in the eye. 
The L-arginine nitric oxide pathway is an important local 
regulator of vascular tone. In the ophthalmic circulation, 
bradykinin is a potent activator of this pathway, and it 
causes pronounced endothelium-dependent relaxations in 
isolated blood vessels (Yao et al 1991; Haeﬂ  iger et al 1992, 
1994), which releases nitric oxide through B2 receptors 
(Meyer et al 1995), and increases in ophthalmic ﬂ  ow in the 
isolated perfused eye (Meyer et al 1993). Stimulation of the 
L-arginin nitric oxide pathway by bradykinin not only leads 
vasodilation but also to the inhibition of migration (Nyborg 
et al 1990) and proliferation of vascular smooth muscle cells 
(Garg and Hassid 1989; Dubey 1994).
It must be emphasized that angiotensin II is also 
assumed to play a role in cerebral myogenic autoregulation 
(Strandgaard and Paulsen 1992). Myogenic autoregulation 
may also be present in the choroidal vasculature (Kiel 1994). 
Hence angiotensin receptor blockade may be useful to pre-
vent abnormal cerebral and ocular autoregulation in patients 
with activated RAS.
ACE inhibitors and diabetic 
retinopathy
Diabetic retinopathy is a major cause of blindness in those 
of working age (Goldstein et al 1993). Diabetic retinopathy 
progresses from a mild non-proliferative form characterized 
by vascular permeability to moderate or severe non-
proliferative diabetic retinopathy in which retinal vessels 
close, and ﬁ  nally to proliferative diabetic retinopathy that 
comprises new blood vessel growth typically between the 
retina and posterior surface of the vitreous.
Angiotensin II is a known stimulus for the expression 
of vascular endothelial growth factor (VEGF), which is 
associated with the induction of retinal neovascularization Clinical Ophthalmology 2007:1(3) 220
Hirooka and Shiraga
(Aiello et al 1995; Gilbert et al 1998; Otani et al 2000; 
Okada et al 2001). Vitreous levels of both angiotensin II and 
VEGF are signiﬁ  cantly higher in eyes with active proliferative 
diabetic retinopathy (PDR) than in eyes with quiescent PDR, 
suggesting that upregulated angiotensin II may be involved 
in the progression of neovascularization (Funatsu et al 2002). 
In experimental diabetic models, inhibition of angiotensin II 
formation with ACE inhibition results in suppression of 
VEGF expression (Moravski et al 2000; Higgins et al 2003). 
Vitreous VEGF levels were higher in patients with 
PDR than in patients without diabetes, but these high levels 
were signiﬁ  cantly reduced after ACE inhibitor treatment 
(Hogeboom et al 2002). A growing number of both clinical 
and experimental studies suggest that inhibition of the RAS 
can provide protective effects against diabetic retinopathy in 
the absence of hypertension. The most widely cited clinical 
evidence for a role of the RAS in diabetic retinopathy in the 
absence of hypertension was produced in the EURODIAB 
Controlled Trial of Lisinopril in Insulin-Dependent Diabetic
Mellitus study (EUCLID), which reported that ACE inhibition 
with lisinopril reduced progression of retinopathy in type I 
diabetic patients who were normotensive (Chaturvedi et al 
1998). This 2-year multicenter study showed that progres-
sion of retinopathy was reduced by at least one level in the 
lisinopril-treated group compared with that in placebo-treated 
control individuals after adjustment for center. This study 
also showed a decreased rate of progression to PDR in the 
lisinopril-treated group after adjustment for glycemic control. 
At 1 month, mean diastolic blood pressure was 74 mmHg 
for the lisinopril-treated group and 77 mmHg in the placebo 
group and this difference was maintained over the course 
of study (EUCLID Study Group 1997). The normotensive 
Appropriate Blood Pressure Control in Diabetes (ABCD) 
study compared the effects on progression of diabetic retinop-
athy obtained with moderate and intensive control of blood 
pressure in normotensive type 2 diabetic patients treated 
with enalapril or nisoldipine (Schrier et al 2002). Follow-up 
blood pressure was 128 mmHg for the intensive treatment 
group and 137 mmHg for the moderate control group. At 
5 years, this prospective study showed that progression of 
diabetic retinopathy was 34% in the intensively treated group, 
compared with 46% in the moderately treated group. No 
signiﬁ  cant difference in response was seen between enalapril- 
and nisoldipine-treated patients. These results showed that 
a decrease in blood pressure in normotensive patients with 
type 2 diabetes was associated with reductions in progres-
sion of diabetic retinopathy. The results of both the EUCLID 
and normotensive ABCD studies show signiﬁ  cant beneﬁ  cial 
effects of ACE inhibition on progress of diabetic retinopathy 
in diabetic patients in the absence of hypertension, but the 
mechanisms that contribute to this response have yet to be 
identiﬁ  ed. Both studies reported a signiﬁ  cant reduction in 
systemic blood pressure. These results may suggest that 
reduction of blood pressure within the normotensive range 
could contribute to the decreases in progression of diabetic 
retinopathy. However, inhibition of the RAS has also been 
shown to effect a number of circulating factors, including 
reactive oxygen species and inﬂ  ammatory cytokines, which 
could indirectly contribute to vascular effects (Koh et al 
2003). In addition, mechanical stretch can activate the AT1 
receptor (Zou et al 2004) and upregulate the VEGF pathway 
in retinal endothelial cells (Suzuma et al 2001), suggesting 
that blood pressure itself may affect actions of the AT1 recep-
tor. The relative contributions of reduced systemic blood 
pressure within the normotensive range and other systemic 
or local ocular effects of RAS inhibitors to the progression 
of diabetic retinopathy remain unknown.
Potential use of ACE inhibitors
in glaucoma treatment
Elevated IOP is the most important risk factor for 
glaucomatous damage, but it is still only a risk factor. 
Visual damage in glaucoma results from a combination of 
elevated IOP and IOP-independent risk factors. Although 
hypothesizing that NTG has an underlying mechanism 
independent of IOP is tempting, use of hypotensive 
treatment strategies does appear to slow the progression 
of NTG (Collaborative Normal-Tension Glaucoma Study 
Group 1998a). However, the ﬁ  ndings of the Collaborative 
Normal Tension Glaucoma Study Group showed no signiﬁ  -
cant association between mean IOP change and visual ﬁ  eld 
progression (Collaborative Normal-Tension Glaucoma Study 
Group 1998a; Collaborative Normal-Tension Glaucoma 
Study Group 1998b).
Even more recently, application of neuroprotection to 
the treatment of non-IOP-dependent glaucomatous damage 
has received increasingly intensive attention. If glaucoma is 
actually a collection of diseases that all result in a common 
optic neuropathy, therapy aimed at preventing the process of 
damage would show enormous therapeutic potential.
ACE inhibitors have recently attracted attention as a new 
class of drugs for the treatment of glaucoma. ACE inhibi-
tors have been shown to lower IOP in patients with ocular 
hypertension or primary open-angle glaucoma (Constad et al 
1988). Lotti and Pawlowski (Lotti and Pawlowski 1990) 
proposed the involvement of prostaglandins in the ocular Clinical Ophthalmology 2007:1(3) 221
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hypotensive effect of enalaprilat. This conclusion was based 
on the ﬁ  nding that indomethacin blocked the IOP-lowering 
effect of enalaprilat. ACE inhibitors are also inhibitors of 
kininase II and thus prevent the breakdown of bradykinin. 
Increased bradykinin levels promote prostaglandin synthe-
sis. Prostaglandin, particularly PGF2α, is known to increase 
uveoscleral outflow of aqueous humor (Crawford and 
Kaufman 1987).
Apoptosis has been shown to be at least one of the 
mechanisms for retinal ganglion cell death in monkey 
models of pressure-induced glaucoma (Quigley et al 1995). 
Evidence for apoptosis in Alzheimer’s disease has been 
provided from both animal models and human materials 
(Schmechel 1999). Longitudinal intervention studies for 
hypertension, such as the Systolic Hypertension in Europe 
(SYST-EUR) study and the Peridopril Protection Against 
Recurrent Stroke Study (PROGRESS) trial, have reported 
a signiﬁ  cant inverse relationship between antihypertensive 
treatments and risk of vascular-related dementia (Forette 
et al 2002; Tzourio et al 2003). For example, SYST-EUR 
data from the 8-year follow-up phase of the program have 
suggested a 55% reduction in risk for dementia during 
long-term active treatment with the ACE inhibitor enala-
pril (Forette et al 2002). Similarly, the PROGRESS study 
indicated that a substantially reduced risk for dementia 
(34%) was conﬁ  rmed by treatment with the ACE inhibitor 
perindopril. Long-term use of ACE inhibitors may have 
a protective role against the development of Alzheimer’s 
disease (Ohrui et al 2004).
Bradykinin has a protective action against glutamate 
neurotoxicity through bradykinin-B2 receptors in cultured 
retinal neurons (Yasuyoshi et al 2004). We have previ-
ously reported that NTG patients were more sensitive to 
exogenous bradykinin than normal subjects (Hirooka et al 
2002). These data suggest that endogenous bradykinin 
levels may be lower in NTG patients than in normal sub-
jects. Angiotensin I-converting enzyme and endothelial 
cell kininase are thought to represent one and the same 
enzyme (Mombouli and Vanhoutte 1995). As a kininase, 
this enzyme is responsible for the degradation of brady-
kinin. ACE inhibitors are thus capable of prolonging the 
half-life of any bradykinin in the proximity of endothelium. 
Long-term treatment with ACE inhibitors increases plasma 
bradykinin levels (Cugno et al 2005). Yasuyoshi et al (2000) 
recently reported that bradykinin has protective effects on 
neurotoxicity induced by glutamate through bradykinin 
B2 receptors in cultured retinal neurons. The protective 
action of bradykinin is mediated by the opening of the 
mitochondrial adenosine triphosphate-sensitive potassium 
channel (Yamauchi et al 2003).
Inhibition of bradykinin degradation by ACE inhibi-
tors may increase the activity of superoxide dismutase 
and modulate the production of nitric oxide, leading to the 
inactivation of reactive oxygen species, while also inhibiting 
various pro-oxidative mechanisms within the vasculature 
(Ehring et al 1994). Lower angiotensin II levels, such as seen 
during treatment with ACE inhibitor, may have beneﬁ  cial 
effects on outcome by lowering vascular superoxide anion 
production (Rajagopalan and Harrison 1996). ACE inhibitor 
may beneﬁ  t vascular function. A previous study reported aver-
age rates of decline in NTG as −0.41 dB per year (Anderson 
et al 2001) with a mean follow-up of 4.5 years. In subjects 
with a signiﬁ  cant decline, mean rate of loss across the entire 
ﬁ  eld was −0.90 dB/year (Anderson et al 2001). In subjects 
who had not progressed, mean rate of loss across the entire 
ﬁ  eld was −0.14 dB/year (Anderson et al 2001). We retro-
spectively reviewed a total of 38 patients with NTG (Hirooka 
et al 2006), divided into 3 groups: control subjects with no 
previous history of hypertension; NTG hypertension patients 
receiving ACE inhibitor; and NTG hypertension patients 
receiving other antihypertensive drug treatment. In the ACE 
inhibitor-treated group, mean deviation (MD) change per 
year was 0.48 ± 0.19 dB, compared to −0.38 ± 0.23 dB in 
control subjects, and −0.50 ± 0.39 dB in the other antihyper-
tensive drug-treated group. These results suggest that ACE 
inhibitors might exert favorable effects on the visual ﬁ  eld in 
patients with NTG (Hirooka et al 2006). ACE inhibitors have 
numerous properties that theoretically should be beneﬁ  cial in 
treating non-IOP-dependent mechanisms in glaucoma.
Randomized, controlled clinical trials have not been per-
formed to clarify neuroprotective effects of ACE inhibitors 
in glaucoma yet. In the absence of such trials, further studies 
in various animal models of glaucoma are also needed.
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